GlobeNewswire: Cellworks Group, Inc. Contains the last 10 of 19 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:57:27ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/06/04/2242099/0/en/Cellworks-CBM-Clinical-Study-Identifies-Novel-Biomarkers-for-ATRA-Benefit-and-Failure-in-AML-Patients.html?f=22&fvtc=4&fvtv=48319Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients2021-06-04T13:00:00Z<![CDATA[Personalized Therapy Biosimulation Predicts with 100% Accuracy ATRA Non-Response in AML Patients with Favorable Genomic Features Personalized Therapy Biosimulation Predicts with 100% Accuracy ATRA Non-Response in AML Patients with Favorable Genomic Features]]>https://www.globenewswire.com/news-release/2021/06/04/2242105/0/en/Cellworks-Singula-Accurately-Predicts-Clinical-Outcome-from-Treatments-in-Patients-with-NSCLC.html?f=22&fvtc=4&fvtv=48319Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC2021-06-04T13:00:00Z<![CDATA[Personalized Therapy Biosimulation Using Multi-Omic Data Predicts OS and PFS for NSCLC Patients Personalized Therapy Biosimulation Using Multi-Omic Data Predicts OS and PFS for NSCLC Patients]]>https://www.globenewswire.com/news-release/2021/06/04/2242107/0/en/Cellworks-Singula-Delivers-Superior-OS-and-DFS-Predictions-for-Brain-Cancer-Patients-in-myCare-022-03-Clinical-Trial.html?f=22&fvtc=4&fvtv=48319Cellworks Singula™ Delivers Superior OS and DFS Predictions for Brain Cancer Patients in myCare-022-03 Clinical Trial2021-06-04T13:00:00Z<![CDATA[Personalized Therapy Biosimulation Using Multi-Omic Data Accurately Predicts Clinical Outcomes for GBM Patients Personalized Therapy Biosimulation Using Multi-Omic Data Accurately Predicts Clinical Outcomes for GBM Patients]]>https://www.globenewswire.com/news-release/2020/12/07/2140778/0/en/Cellworks-CBM-Biosimulation-Identifies-Genomic-Causes-for-Induction-Failure-in-AML-Patients-and-Suggests-Alternative-Therapies.html?f=22&fvtc=4&fvtv=48319Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies2020-12-07T16:00:00Z<![CDATA[myCare-021-02 study discovers patient-specific resistance mechanisms that can inform treatment planning and improve AML patient outcomes myCare-021-02 study discovers patient-specific resistance mechanisms that can inform treatment planning and improve AML patient outcomes]]>https://www.globenewswire.com/news-release/2020/12/07/2140779/0/en/Cellworks-Personalized-Biosimulation-Clinical-Trial-Predicted-ATO-and-ATRA-Therapy-Response-in-APL-Patients-with-93-Accuracy.html?f=22&fvtc=4&fvtv=48319Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy2020-12-07T16:00:00Z<![CDATA[myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL patients and can identify patient-specific biomarkers in non-responders myCare-021-01 study found CBM has high accuracy for predicting therapy response in APL patients and can identify patient-specific biomarkers in non-responders]]>https://www.globenewswire.com/news-release/2020/12/07/2140781/0/en/Cellworks-Personalized-Biosimulation-Clinical-Trials-Achieve-90-Therapy-Response-Prediction-Accuracy-for-AML-and-MDS-Patients.html?f=22&fvtc=4&fvtv=48319Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients2020-12-07T16:00:00Z<![CDATA[myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and sensitivity in predicting complete response to physician prescribed therapies for AML and MDS patients myCare-020-01 and myCare-020-02 studies show Cellworks Singula™ has high accuracy and sensitivity in predicting complete response to physician prescribed therapies for AML and MDS patients]]>https://www.globenewswire.com/news-release/2020/12/07/2140785/0/en/Cellworks-CBM-Identifies-Genomic-Signatures-Impacting-HOXA-Regulation-that-Determine-Response-for-AML-Patients-with-Monosomy-7.html?f=22&fvtc=4&fvtv=48319Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 72020-12-07T16:00:00Z<![CDATA[myCare-021-04 study finds genetic signatures associated with 100% remission rate fromAML induction therapy despite presence of Monosomy 7]]>https://www.globenewswire.com/news-release/2020/05/29/2040897/0/en/myCare-Clinical-Studies-Show-Cellworks-Singula-Achieves-Superior-Therapy-Response-Predictions-for-Brain-Cancer-Patients.html?f=22&fvtc=4&fvtv=48319myCare Clinical Studies Show Cellworks Singula™ Achieves Superior Therapy Response Predictions for Brain Cancer Patients2020-05-29T12:00:00Z<![CDATA[Cellworks Multi-omics Biosimulation Delivers GBM and LGG Survival Predictors Above and Beyond Physician Prescribed Treatments Cellworks Multi-omics Biosimulation Delivers GBM and LGG Survival Predictors Above and Beyond Physician Prescribed Treatments]]>Cellworks GBM PFSCellworks GBM PFShttps://www.globenewswire.com/news-release/2020/05/14/2033462/0/en/Cellworks-Singula-Predicts-Personalized-Therapy-Responses-for-Pancreatic-Cancer-Patients-with-94-Accuracy.html?f=22&fvtc=4&fvtv=48319Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy2020-05-14T12:00:00Z<![CDATA[myCare Study Shows Cellworks Multi-omics Biosimulation is a Superior Predictor of Therapy Response in PDAC Patients Compared to Physician Prescribed Treatment]]>https://www.globenewswire.com/news-release/2020/05/14/2033464/0/en/Cellworks-Singula-Predicts-Personalized-Therapy-Responses-for-AML-and-MDS-Patients-with-Higher-Accuracy-than-Physician-Prescribed-Treatments.html?f=22&fvtc=4&fvtv=48319Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments2020-05-14T12:00:00Z<![CDATA[myCare Studies Show Cellworks Multi-omics Biosimulation is a Superior Predictor of Complete Response to Therapies for AML and MDS Patients myCare Studies Show Cellworks Multi-omics Biosimulation is a Superior Predictor of Complete Response to Therapies for AML and MDS Patients]]>